Femasys Inc (FEMY): Cost of Revenue

Annual figures by period end, from SEC filings.

$872.4K

Year ended 2025-12-31

$898.0K

Trailing 12 months to 2026-06-30

+25.4%

3-year compound annual growth

+23.3%

5-year compound annual growth

2020-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$872.4K	+60.1%	2026-03-31, From 2025-01-01
2024-12-31	$544.9K	+43.4%	2026-03-31, From 2024-01-01
2023-12-31	$380.1K	-14.0%	2025-03-27, From 2023-01-01
2022-12-31	$441.9K	+19.3%	2024-03-28, From 2022-01-01
2021-12-31	$370.4K	+20.8%	2023-07-24, From 2021-01-01
2020-12-31	$306.5K	n/a	2022-03-24, From 2020-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Femasys Inc (FEMY)	2025-12-31	$872.4K	+60.1%
QHSLab, Inc. (USAQ)	2025-12-31	$880.9K	+13.8%
Vycor Medical Inc (VYCO)	2025-12-31	$302.3K	+81.2%
OSR Health, Inc. (OSRH)	2025-12-31	$2.31M	-14.9%
EBR Systems, Inc. (NONE.)	2025-12-31	$1.13M	n/a
Nuo Therapeutics, Inc. (AURX)	2025-12-31	$1.10M	+261.8%
IceCure Medical Ltd. (ICCM)	2025-12-31	$2.15M	+17.0%
Tenon Medical, Inc. (TNON)	2025-12-31	$1.59M	+1.3%
Intelligent Bio Solutions Inc. (INBS)	2026-06-30	$2.17M	+19.9%

Compare FEMY, USAQ, VYCO, OSRH side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗